labcorp america hold
labcorp america lead provid diagnost test inform servic
result solid revenu ep close expect
importantli test volum manag care contract chang stabl
sequenti despit weak consum genet test
expect flat year covanc drug develop
perform well organ growth backlog continu build
nice expect convert next month diagnost
margin improv sequenti give us confid guidanc remain
sidelin due near-term volum price headwind
maintain hold rate rais price target
result nutshel revenu increas y/i
lower estim consensu
covanc drug develop revenu increas y/i
vs consensu bp y/i adjust oper
margin expans net book-to-bil ratio
sequenti adjust ep penni higher
consensu penni lower estim
labcorp diagnost revenu decreas
lower estim total volum decreas bp
organ volum decreas primarili due bp headwind
lower consum genet demand bp pressur
manag care contract chang horizon bc/b bp
headwind lower y/i strength revenu day strength revenu
day expect flat y/i provid one day benefit
lh expect consum genet demand flat
volum horizon expect remain stabl throughout
adjust divestitur revenu per requisit increas
would adjust bp impact pama
test mix strong non-consum genet allergi oncolog cdx
women health medic drug monitor
meet consum want met labcorp continu
roll-out walgreen retail locat expect
walgreen store end locat end
labcorp also expand consum offer area includ
new consum initi phlebotomy-bas test pixel labcorp
new collabor mount sinai digit patholog artifici
intellig signific opportun labcorp
improv qualiti care increas optim patholog resourc
